New Lung Cancer Drug Combo Cuts Tumor Progression Risk by 65% in Phase 3 Trial
A Merck-Kelun antibody-drug conjugate paired with immunotherapy slashed tumor progression risk in untreated advanced lung cancer patients.
Summary
A new cancer drug called sacituzumab tirumotecan, developed by Kelun-Biotech and licensed to Merck, reduced the risk of lung tumor progression by 65% in a Phase 3 clinical trial. The study focused on patients with advanced non-small cell lung cancer who had not yet received treatment. Crucially, this is the first time an antibody-drug conjugate — a targeted form of chemotherapy — has been successfully combined with a PD-1 immunotherapy drug in this patient group. Early data also hints at a survival benefit, though longer follow-up is needed to confirm this. The trial was conducted in China and results were reported ahead of the ASCO oncology conference, signaling a potentially significant advance in first-line lung cancer treatment.
Detailed Summary
Lung cancer remains one of the leading causes of cancer-related death worldwide, and new treatment options for advanced, previously untreated cases are urgently needed. A Phase 3 clinical trial has now shown that a novel drug combination can dramatically slow disease progression, offering renewed hope for patients and clinicians alike.
The drug at the center of the trial is sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate (ADC) developed by China-based Kelun-Biotech and licensed to pharmaceutical giant Merck. ADCs work by attaching a chemotherapy payload directly to an antibody that targets cancer cells, allowing more precise delivery of toxic agents while sparing healthy tissue. In the Phase 3 study, sac-TMT was combined with a PD-1 checkpoint inhibitor — a class of immunotherapy that helps the immune system recognize and attack cancer cells.
The headline result: a 65% reduction in the risk of tumor progression compared to the control arm. A preliminary survival advantage was also observed in patients receiving the Kelun-Merck combination, though this finding requires longer follow-up before it can be considered statistically confirmed. The trial enrolled patients with advanced non-small cell lung cancer (NSCLC) who had not previously received systemic treatment.
This is described as the first successful Phase 3 combination of an ADC with PD-1 immunotherapy in untreated advanced NSCLC — a clinically meaningful milestone in a competitive treatment landscape. For a health-conscious audience tracking cancer prevention and treatment science, this represents a meaningful shift in what first-line therapy may look like in coming years.
Important caveats apply: the trial was conducted entirely in China, raising questions about generalizability to Western populations. Full data has not yet been published in a peer-reviewed journal, and the survival benefit remains preliminary. Independent replication and regulatory review will be essential before this becomes a global standard of care.
Key Findings
- Sacituzumab tirumotecan cut lung tumor progression risk by 65% versus control in Phase 3 trial.
- First successful ADC plus PD-1 immunotherapy combo in previously untreated advanced non-small cell lung cancer.
- A preliminary overall survival benefit was observed but requires longer follow-up to confirm.
- Trial was conducted in China; generalizability to diverse global populations remains to be established.
- Results were released ahead of the ASCO oncology conference, signaling high clinical significance.
Methodology
This is a news report from STAT News summarizing a Phase 3 randomized clinical trial abstract submitted to the ASCO oncology conference. STAT News is a credible, specialized health and science outlet. The article is based on abstract-level data; full peer-reviewed publication is pending.
Study Limitations
The trial was conducted exclusively in China, which may limit applicability to non-Asian populations with different genetic and environmental risk profiles. Full peer-reviewed data has not been published; ASCO abstract results can sometimes differ from final published findings. The survival benefit is preliminary and requires confirmation with extended follow-up data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.